Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR20220749784202-HEM-201A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell DiseaseA Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of FT-4202 in Patients with Thalassemia or Sickle Cell DiseaseInterventionalPending18/01/2022
LBCTR2021104870SBS-2021-0102The effectiveness, mechanisms of change, and acceptability of Family Focused PsychoSocial Support for at-risk adolescents in LebanonThe effectiveness, mechanisms of change, and acceptability of Family Focused PsychoSocial Support for at-risk adolescents in LebanonInterventionalPending13/10/2021
LBCTR2019020179PTG300-02A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects with Chronic Anemia A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects with Chronic Anemia InterventionalComplete02/01/2019
LBCTR2019070220PTG300-03An Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia SubjectsAn Open Label Extension Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia SubjectsInterventionalComplete03/04/2019
LBCTR2020104517ALN-TTRSC02-003 Helios-B : A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyHelios-B: A Phase 3, Randomized, Doubleblind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)InterventionalComplete10/07/2020
LBCTR2020043435DCR-PHXC-201Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary HyperoxaluriaPhase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (subcutaneous use) in Patients with Primary HyperoxaluriaInterventionalComplete19/03/2020
LBCTR2020021295VIT-2763-THAL-201A study to evaluate if VIT-2763 may be beneficial in the treatment of Nontransfusion Dependent Beta-thalassaemia.A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of VIT-2763 in Subjects with Non-transfusion Dependent Beta-thalassaemiaInterventionalComplete02/10/2019
LBCTR2022035012BIO-2021-0404Changes of Resting Metabolic Rate in University AthletesChanges of Resting Metabolic Rate in University AthletesInterventionalPending14/03/2022
LBCTR2022035014TRACE 2020-9591Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon.Real-World Evidence Study on AbeMaciclib Treatment Patterns and Effectiveness in Patients with HR+/HER2- Locally Advanced or Metastatic BReAst CancEr in Kuwait and Lebanon.ObservationalRecruiting16/03/2022
LBCTR2019020193CLMB763X2202A randomized patient-and-physician blinded, placebo- controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathyA randomized patient-and-physician blinded, placebo- controlled, 24-week study to assess the safety, tolerability and efficacy of LMB763 in patients with diabetic nephropathyInterventionalComplete09/02/2019
items per page71 - 80 of 174 items